جست‌وجوی استاد و پژوهشگر

• Urology
• Prostate Cancer
• Bladder Cancer
• +۹ مورد دیگر

Christopher A Warlick is a Professor and Head of the Department of Urology at the University of Minnesota Medical School. He is a leading expert in prostate and bladder cancer, with a strong focus on cancer screening, prevention, active surveillance, and novel therapeutic strategies including focal and immune-mediated treatments. Research Interests: Prostate Cancer Etiology and Survivorship Bladder Cancer Management Active Surveillance and Risk Stratification Minimally Invasive and Focal Therapies Transurethral Ablation Techniques Immunotherapy for Advanced Prostate Cancer His recent publications reflect a consistent and impactful research trajectory, emphasizing clinical trials, surgical outcomes, and innovative diagnostics. Themes include comparative effectiveness of robotic vs open surgery, microbiome implications in prostate cancer, and AI-driven therapeutic development. His work bridges clinical practice and translational research, with strong industry and multi-institutional collaborations. Scientific Awards and Recognition: No specific awards listed in the provided text. Advising and Grants: Dr. Warlick serves as Principal Investigator on multiple funded research projects, including a Phase II randomized trial (HEAT study), a multicenter ablation pilot, and an AI-designed mini-protein project funded by the U.S. Department of Defense. He collaborates with institutions such as Johns Hopkins University and industry partners including MacroGenics Inc., Francis Medical, Inc., and Photocure Inc. While formal student advisees are not listed, his role as PI indicates mentorship of junior researchers and clinical fellows. Labs and Research Teams: Dr. Warlick leads a multidisciplinary research team focused on urologic oncology, with active projects spanning from early detection to advanced therapeutics. His work is supported by a robust network of clinical collaborators, bioengineers, and data scientists, particularly in the areas of imaging, immunotherapy, and surgical innovation.

Irfan Çelebiمشاهده پروفایل

استاد

• Radiology
• Diagnostic Imaging
• Head and Neck Radiology
• +۳ مورد دیگر

Irfan Çelebi is a Professor and Department Head of Radiology at Beykent University, with active research in diagnostic imaging techniques and clinical applications. His work bridges radiology with otolaryngology, surgery, and infectious disease management through advanced imaging modalities. His research focuses on head and neck radiology, particularly CT/MRI applications for laryngeal carcinoma, sinusitis, and parotid gland disorders. Key interests include quantitative imaging biomarkers for surgical outcomes, ultrasound in obstetrics/musculoskeletal conditions, and radiological correlations with pathological findings. He frequently explores anatomical variations and their clinical implications in sinus drainage pathways and neck masses. Analysis of his recent publications reveals dominant themes in head/neck oncology imaging, with significant contributions to predicting laryngectomy complications and preepiglottic space invasion. His COVID-19-related work demonstrates adaptability to emerging infectious disease challenges, while persistent exploration of ultrasound applications spans obstetrics, Baker's cysts, and reflux diagnosis. No scientific awards were documented in the provided materials. Information regarding student advising, research grants, laboratory facilities, or collaborative teams was not mentioned in the source text.

Laura M. Douglassمشاهده پروفایل

دانشیار

• Reconstructive Urology
• Gender-Affirming Surgery
• Urologic Trauma
• +۳ مورد دیگر

Laura M. Douglass, MD is an Associate Professor in the Department of Urology at Lewis Katz School of Medicine, Temple University, where she also serves as Co-Director of the Transgender Program at Temple Health. Her clinical practice focuses on reconstructive urology and gender-affirming surgery. Dr. Douglass completed her medical degree at Tulane University School of Medicine, followed by residency training in Urologic Surgery at Montefiore Medical Center/Albert Einstein College of Medicine, and a Fellowship in Reconstructive Urology at Temple University. She is board-certified by the American Board of Urology. Her research interests span genitourinary reconstruction , prosthetic urology , and gender-affirming surgical techniques , with particular expertise in urethral stricture management, urinary incontinence treatments, and surgical innovations for transgender patients. Her publications demonstrate strong focus on surgical education and oncologic urology. Honors include: 2022 Health Equity Leadership & Social Justice Award Arnold P. Gold Humanism in Medicine Award Tulane University School of Medicine Merit Scholarship She maintains active memberships in the American Urological Association, Society for Women in Urology, Society of Genitourinary Reconstructive Surgeons, and World Professional Association for Transgender Health.

• Urologic Oncology
• Prostate Cancer
• Bladder Cancer
• +۵ مورد دیگر

Dr. Bashir Al Hussein is an Assistant Professor of Urology and Population Health Sciences at Weill Cornell Medicine, Cornell University, and serves as Assistant Attending Urologist at NewYork-Presbyterian Hospital. Specializing in urologic oncology, he manages genitourinary malignancies including prostate, kidney, and bladder cancers using robotic and open surgical approaches tailored to disease complexity. M.P.H. in Epidemiology, Vanderbilt University School of Medicine (2024) M.D., University of Jordan, Faculty of Medicine (2012) His research applies epidemiologic methods to optimize cancer care quality, focusing on decision-making processes , survivorship outcomes , and health literacy in urologic malignancies. Key investigations examine socioeconomic disparities in treatment access, functional recovery post-surgery, and policy impacts on cancer care affordability. This work bridges clinical practice with population health to enhance patient-centered care delivery. Recent publications (2024-2025) reveal dominant trends in prostate cancer management: Increasing adoption of active surveillance for low-risk cases Racial/ethnic disparities in treatment intensity Functional outcomes as critical treatment metrics Policy impacts on drug affordability (e.g., Inflation Reduction Act) Gender inequality in clinical trial leadership Health literacy's role in cancer mortality His bladder cancer research emphasizes novel immunotherapies for BCG-unresponsive disease. American Urological Association Research Scholar Award As Director of the Adult Urology Clinic and The Ronald Stanton Clinical Scholar, Dr. Al Hussein leads quality improvement initiatives while mentoring trainees. His grant portfolio includes health services research examining treatment decision-making and disparities, supported by institutional and professional society awards. Current projects analyze socioeconomic determinants of cancer outcomes and optimize survivorship care pathways. He collaborates with multidisciplinary teams across Weill Cornell's Department of Urology and Population Health Sciences, contributing to clinical operations, research design, and educational programs focused on advancing equitable urologic cancer care through surgical innovation and population health strategies.

• Pharmacoepidemiology
• Clinical Pharmacology
• Oncology
• +۵ مورد دیگر

Dr. Ewoudt van de Garde is an Associate Professor of Clinical Pharmacotherapy at the Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University. He also serves as a Hospital Pharmacist at St. Antonius Hospital in Utrecht/Nieuwegein and is board certified as both a Clinical Pharmacologist and Epidemiologist. His academic career spans over 15 years with significant contributions to pharmacoepidemiology and clinical pharmacology. Dr. van de Garde completed his pharmacy degree in 2002 and began his training as a hospital pharmacist at St. Antonius Hospital in 2003 while conducting doctoral research on lower respiratory tract infections. He earned his doctorate in 2007, obtained his epidemiology certification in 2008, and became a medical staff member at St. Antonius Hospital that same year. Since 2012, he has maintained a part-time academic position at Utrecht University while continuing his hospital work. In 2016, he obtained his clinical pharmacology designation and became a hospital pharmacy trainer. Dr. van de Garde's primary research focus is on understanding how pre-marketing authorization clinical trial results translate to real-world outcomes. He conducts efficacy-effectiveness studies primarily in the fields of oncology and inflammatory diseases . His current work also explores applying real-world outcomes data in shared decision making with patients and developing machine learning techniques to shorten the time to appropriate efficacy-effectiveness assessment. Previously, he established and conducted numerous studies to improve clinical outcomes in patients with community-acquired pneumonia. His recent publications reveal a strong focus on comparative effectiveness research across multiple disease areas. In oncology, he examines immunotherapy effectiveness in non-small cell lung cancer and treatment outcomes in bladder cancer. In infectious diseases, his work centers on community-acquired pneumonia management and antibiotic utilization. His methodological contributions include developing text mining algorithms for real-world data analysis and evaluating clinical decision support systems. Member, Scientific Advisory Board of Dutch Healthcare Institute (ZiN) Member, Scientific Advisory Board of Lung Foundation Netherlands (Longfonds) Member, Study Program Committee of School of Pharmacy (UU) Member, several task forces of Netherlands Society of Hospital Pharmacy (NVZA) Dr. van de Garde actively contributes to pharmacotherapy education within the Master's program in Pharmacy. He serves as chair of the Clinical Pharmacy course, is a member of the Program Committee of the School of Pharmacy, and conducts research on the selection process for the pharmacy program. He has supervised over 50 theses and co-supervised 8 PhD students. His research has been supported by grants including a ZonMw grant to investigate the feasibility of an infrastructure for research into real-world clinical effectiveness of pharmacotherapy, which led to the Santeon Pharmadatabase. His research group collaborates across multiple institutions through the Santeon network, which combines data from seven large teaching hospitals in the Netherlands. This infrastructure enables large-scale real-world evidence studies across various therapeutic areas.

• Bladder Cancer
• Non Muscle Invasive Bladder Cancer
• Molecular Biomarkers
• +۶ مورد دیگر

Dr. Tahlita Zuiverloon is an active researcher in the Urology department at Erasmus MC, with a primary focus on bladder cancer research. Her work spans molecular biology, clinical oncology, and translational medicine, with particular emphasis on non-muscle invasive bladder cancer. Her research interests center around identifying molecular biomarkers for cancer progression and treatment response prediction. Dr. Zuiverloon investigates the molecular mechanisms underlying bladder cancer development and progression, with special attention to therapeutic targets and predictive biomarkers for treatments like BCG immunotherapy. Her work also extends to testicular germ cell tumors and the application of artificial intelligence in pathology for improved diagnostic accuracy. Analysis of her recent publications (2025) reveals a strong trend toward translational research that bridges molecular findings with clinical applications. Her work spans from basic molecular studies on ARID1A loss in bladder cancer to large international multicenter clinical validation studies using AI-powered pathology assays. The predominant fields covered include urological oncology, molecular diagnostics, immunotherapy response prediction, and cancer biomarker discovery. Dr. Zuiverloon maintains active collaborations across multiple institutions, as evidenced by her international multicenter studies. Her research has been featured in high-impact journals including Nature Reviews Urology , Journal of Urology , and European Urology , with significant attention from both academic and clinical communities.

• Pediatric Surgery
• Minimally Invasive Surgery
• Pediatric Urology
• +۷ مورد دیگر

Prof. Dr. Bekir Haluk Güvenç is a distinguished Professor of Pediatric Surgery with over three decades of clinical and academic experience. He graduated from Istanbul University Faculty of Medicine in 1986 and completed his specialization in Pediatric Surgery at the same institution in 1992. Since March 2025, he has been serving in the Department of Pediatric Surgery at his current institution, continuing his extensive career that spans multiple prestigious academic medical centers including Istanbul University, Kocaeli University, and Bülent Ecevit University. Medical Degree: Istanbul University Faculty of Medicine (1986) Specialization: Pediatric Surgery, Istanbul University (1992) Prof. Güvenç's research interests span the entire spectrum of pediatric surgical care, with particular expertise in minimally invasive techniques including laparoscopic and thoracoscopic procedures. His work has significantly contributed to advancing pediatric urological surgery, neonatal surgical care, gastrointestinal surgery, and tumor surgery. He has pioneered techniques in inguinal hernia repair, management of undescended testis, and treatment of complex pediatric conditions through minimally invasive approaches. His research program focuses on improving surgical outcomes while minimizing trauma to young patients. An analysis of his most recent publications reveals a strong focus on diagnostic accuracy in pediatric appendicitis, innovative approaches to congenital abnormalities, and advancements in surgical techniques. His work bridges basic science research in tissue engineering with clinical applications, particularly in bladder smooth muscle cell research and postoperative nutritional management. Prof. Güvenç continues to push the boundaries of pediatric surgical care through both clinical innovation and scholarly contributions. Türkiye Çocuk Cerrahisi Derneği, Prof. Dr. Akgün Hiçsönmez Bilimsel Araştırma Ödülü (2002) Türkiye Çocuk Cerrahisi Derneği, Prof. Dr. İhsan Numanoğlu Bilimsel Araştırma Ödülü (2005) Throughout his career, Prof. Güvenç has been actively involved in surgical education and training of future pediatric surgeons. He has participated in numerous national and international conferences as a speaker and workshop leader, sharing his expertise in laparoscopic techniques and pediatric surgical management. His research collaborations span multiple institutions and have resulted in significant contributions to the understanding and treatment of complex pediatric surgical conditions. He has also investigated perioperative anxiety management strategies, demonstrating his commitment to holistic patient and family-centered care.

• Prostate Cancer
• Bladder Cancer
• Chemotherapy
• +۴ مورد دیگر

Sarah Pirrie serves as a Principal Biostatistician at the Cancer Research UK Clinical Trials Unit within the College of Medical and Dental Sciences at the University of Birmingham. With 42 research outputs and involvement in 14 active projects through 2034, she plays a critical role in advancing cancer clinical trials methodology and statistical analysis. Her research expertise spans multiple oncology domains: Urological cancers (Bladder Cancer, Prostate Cancer) Cancer treatment modalities (Chemotherapy, Zoledronic Acid, Strontium-89) Survival analysis and clinical outcomes measurement Medical imaging applications in cancer staging Analysis of her recent publications reveals a strong emphasis on optimizing cancer treatment pathways through advanced imaging techniques and innovative clinical trial designs. Her work frequently addresses methodological challenges in comparative effectiveness research, with particular attention to bladder cancer diagnostics and treatment stratification. Ms. Pirrie serves as a key researcher on major national and international projects including the BladderPath trial, FaR-RMS study for Rhabdomyosarcoma, Thrombo-STOP for lung cancer patients, and the RadIO Trial for bladder cancer treatment. Her statistical expertise has contributed to trial designs that have garnered significant attention in both academic and clinical communities.

• Cystectomy
• Non-Muscle-Invasive Bladder Cancer
• Transitional Cell Carcinoma
• +۵ مورد دیگر

Patrick Hensley, MD is an Assistant Professor in the Department of Urology at the University of Kentucky , with a joint appointment in Pathology and Lab Medicine . He is actively involved with the Markey Cancer Center and the Translational Oncology Research Program . Education: Doctor of Medicine (2015), University of Kentucky Bachelor of Science (2010), Miami University Postdoctoral Fellowship, MD Anderson Cancer Center Dr. Hensley specializes in bladder cancer research , focusing on Non-Muscle-Invasive Bladder Cancer (NMIBC) and Muscle-Invasive Bladder Cancer (MIBC) . His work integrates artificial intelligence in pathology for predictive diagnostics and explores neoadjuvant chemotherapy efficacy. Current Projects: Phase 1/2 Study of Erdafitinib Intravesical Delivery (Janssen Pharmaceuticals) ABLE-32 Trial (Ferring Pharmaceuticals): Nadofaragene Firadenovec for intermediate-risk NMIBC Intravesical Enfortumab Vedotin Study (Seagen Incorporated) Key Awards: William Stamps Farish Faculty Fellowship Fund in Urologic Cancer

David Pookمشاهده پروفایل

دانشیار

• Oncology
• Genitourinary Cancers
• Prostate Cancer Research
• +۳ مورد دیگر

A/Prof David Pook is an Associate Professor and Medical Oncologist at Monash University, affiliated with the School of Clinical Sciences and the Department of Anatomy and Developmental Biology. His work focuses on clinical and translational research in prostate cancer, particularly the development of novel therapies for genitourinary malignancies. He leads the Prostate Cancer Research Program and holds an external position as a Medical Oncologist at Monash Health since 2010. Education : MBBS (Hons), University of Tasmania BMedSci, University of Tasmania MD (Targeting Therapy in Colon Cancer), University of Melbourne FRACP, Royal Australasian College of Physicians (RACP) Research Interests : Dr. Pook’s research emphasizes identifying and testing novel therapeutic agents for genitourinary cancers, including prostate cancer. His work spans radiopharmaceuticals (e.g., Lu-PSMA), immunotherapies (e.g., checkpoint inhibitors), and combination therapies. He also explores cardiovascular risks associated with androgen deprivation therapy and long-term outcomes in metastatic hormone-sensitive prostate cancer. Recent Projects : Monash Cancer Donor Program (2025–2026) rechARge Trial (Phase 3, BMS-986365 vs. docetaxel in mCRPC) Disitamab Vedotin in HER2-expressing urothelial carcinoma Xaluritamig for high-risk prostate cancer recurrence Grants & Funding : Dr. Pook is a Primary Chief Investigator for over 40 projects, including major studies funded by industry and national health bodies. Labs/Teams : He leads the Prostate Cancer Research Program and collaborates with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

• Smoking cessation
• Aboriginal people
• Oral health
• +۱ مورد دیگر

Ratika Kumar is Senior Research Fellow at Southern Cross University's Faculty of Health and ECR fellow at The Regional Australia Mental Health Research and Training Institute (RAMHeaRT). Her research expertise spans quantitative and qualitative methods in tobacco control, mental health, and oral health. Current work focuses on evaluating the iSISTAQUIT social media campaign's effectiveness in training health providers to deliver culturally sensitive smoking cessation support to pregnant Indigenous women. This includes designing evaluation frameworks, assessing campaign reach, and analyzing stakeholder engagement strategies. Publications demonstrate diverse methodological approaches across health domains, including randomized trials in primary care settings, diagnostic imaging applications, environmental exposure studies, and clinical oncology research. Collaborative projects reflect interdisciplinary engagement with cardiology, oncology, environmental science, and public health.

Amir Horowitzمشاهده پروفایل

استادیار

• Natural Killer Cell Immunology
• T Cell Immunology
• Cancer Immunology
• +۳ مورد دیگر

Amir Horowitz is an Assistant Professor in the Oncological Sciences department at the Icahn School of Medicine at Mount Sinai . He works within the Graduate School of Biomedical Sciences and is affiliated with the Tisch Cancer Institute and the Marc and Jennifer Lipschultz Precision Immunology Institute . Research areas: Natural Killer Cell Immunology, T Cell Immunology, Bladder Cancer, HLA Genetics Key institutions: Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute Horowitz's research focuses on immune cell biology and cancer immunogenetics , particularly involving NK cells , HLA molecules , and CD8+ T cell interactions . He investigates how genetic dimorphisms influence disease severity in both infections and malignancies. Recent work includes HLA-B polymorphism analysis in COVID-19 severity , HLA-E epitope mapping , and bladder cancer treatment optimization . His publications span immunology, oncology, and radiology journals with high citation impact. Current affiliation: Icahn School of Medicine at Mount Sinai (2004-present) Collaboration networks: Global (multiple international co-authors visible)

• Pharmacology
• Toxicology
• Pharmaceutical Science
• +۵ مورد دیگر

Murphy Wan is a postdoctoral fellow at the Faculty of Medicine, Lund University , affiliated with the Division of Microbiology, Immunology and Glycobiology (MIG) and Cancer Infection. Their research spans pharmacology, immunology, and oncology, focusing on natural compounds for disease prevention, host-pathogen interactions, and cancer therapies. Key Roles: Postdoctoral Fellow, Research Fellow Institution: Lund University, Sweden Their work contributes to the UN Sustainable Development Goals, particularly in health and well-being (SDG 3) and life on land (SDG 15). Research interests include the pharmacokinetics of Schisandra chinensis lignans, modulation of immune responses by toxins like deoxynivalenol, and MYC inhibition mechanisms in disease. Recent publications highlight investigations into: Schisandra chinensis lignans for disease prevention Deoxynivalenol's impact on mucin and cytokines Multitarget MYC inhibition by bacterial proteases Alpha1-oleate in bladder cancer treatment Drug interactions in colorectal cancer models Collaborations extend across disciplines (immunology, microbiology, oncology) and geographies, with external partnerships in Europe, North America, and Asia. Their studies integrate molecular biology, clinical applications, and food science to address infectious and oncological challenges.

• Bladder Cancer
• Urologic Oncology
• Robot-Assisted Surgery
• +۶ مورد دیگر

Knud Fabrin serves as a Clinical Professor in the Department of Urology within the Faculty of Medicine at Aalborg University Hospital. His primary clinical and research focus centers on advanced urologic oncology, particularly bladder cancer management requiring radical cystectomy and innovative surgical techniques. Affiliated with Denmark's national healthcare system, he actively participates in multicenter Nordic collaborations including the NorCys and DaBlaCa trials. His research interests prominently feature Bladder Cancer and Robot-Assisted Surgery , with significant contributions to optimizing neoadjuvant chemotherapy protocols, surgical reconstruction techniques (particularly ileal conduit variations), and postoperative complication management. Current work investigates ctDNA biomarkers for immunotherapy timing and compares retrosigmoid versus conventional urinary diversion methods in robot-assisted cystectomies. Analysis of his 2024 publications reveals strong emphasis on Real-world implementation of evidence-based bladder cancer care Technical refinements in robotic cystectomy Nordic collaborative research frameworks Translational applications of molecular diagnostics His work bridges clinical practice with rigorous trial methodology across Denmark and the Nordic region. Professional activities include participation in the 2012 EAU Robotic Urology Section Congress, demonstrating longstanding engagement with robotic surgical advancements. Current research output shows accelerating contributions to high-impact urologic oncology literature through both journal articles and conference presentations.

Sima Portenمشاهده پروفایل

استادیار

• Urologic Oncology
• Genitourinary Cancer
• Bladder Cancer
• +۷ مورد دیگر

Dr. Sima Porten is a specialist in genitourinary cancers and a faculty member in the Department of Urology at the University of California San Francisco (UCSF) School of Medicine. She is part of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center, where she focuses on the diagnosis and treatment of bladder, kidney, and high-risk prostate cancers. Her research is centered on the biological and genetic mechanisms of urothelial carcinoma, aiming to develop personalized diagnostic tools and therapies. She has published extensively on topics including urine biomarkers, molecular imaging, health disparities, and treatment outcomes in bladder cancer. Her work integrates clinical practice, translational research, and health services to improve patient care. Dr. Porten’s recent publications reveal a strong focus on non-invasive diagnostics, molecular profiling, equity in cancer care, and innovative clinical trial design. Her research spans immunology, genetics, imaging, and patient-reported outcomes, reflecting a multidisciplinary approach to advancing bladder cancer management. Howard Hughes Medical Institute Research Scholar, NIH (2003) Alpha Omega Alpha Honor Society (2006) Julius R. Krevans Award for Clinical Excellence (2012) John Quale Travel Fellowship (2015) William R. Smart Distinguished Teaching Award (2017) Best Reviewer Award, Journal of Urology (2017) New Investigator Scholarship-Leadership Award, ALLIANCE Foundation (2019) Muriel Steele Society Honor (UCSF) Dr. Porten has been involved in major multi-institutional research collaborations and clinical trials, including SWOG S1605 and ECOG-ACRIN EA8212, contributing to national efforts in standardizing care and evaluating novel therapies. She has received grant support through awards such as the Faculty Learning and Development Fund and the ALLIANCE Foundation. While no direct mention of advising students is made, her leadership in research and teaching suggests a mentorship role within the department. She is actively engaged in professional societies including the American Urological Association and the Society of Urologic Oncology. Dr. Porten is affiliated with the UCSF Department of Urology and the Helen Diller Family Comprehensive Cancer Center, where she contributes to a multidisciplinary team advancing research and clinical care in urologic oncology.